|
NLN expression based on
|
Statistics: Unpaired two sample T-test was employed to evaluate levels of significance in expression level between any two sample groups
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.35940000051727E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.41950000004587E-06 |
| Normal-vs-Stage2 |
5.764100E-02 |
| Normal-vs-Stage3 |
1.432150E-04 |
| Normal-vs-Stage4 |
7.991900E-02 |
| Stage1-vs-Stage2 |
6.357200E-01 |
| Stage1-vs-Stage3 |
9.402600E-01 |
| Stage1-vs-Stage4 |
4.015800E-01 |
| Stage2-vs-Stage3 |
6.124000E-01 |
| Stage2-vs-Stage4 |
8.000600E-01 |
| Stage3-vs-Stage4 |
3.839600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.66249999614621E-08 |
| Normal-vs-AfricanAmerican |
6.161900E-02 |
| Normal-vs-Asian |
1.351410E-01 |
| Caucasian-vs-AfricanAmerican |
9.307200E-01 |
| Caucasian-vs-Asian |
1.461780E-01 |
| AfricanAmerican-vs-Asian |
4.049400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.562400E-03 |
| Normal-vs-Female |
4.64710000036561E-07 |
| Male-vs-Female |
2.473600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.71339999999187E-06 |
| Normal-vs-Age(41-60Yrs) |
1.362320E-03 |
| Normal-vs-Age(61-80Yrs) |
4.499900E-03 |
| Normal-vs-Age(81-100Yrs) |
1.742250E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.003500E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.508600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.659000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.423000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.290600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.864600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.300600E-01 |
| Classical-VS-Follicular |
2.98489999994711E-06 |
| Classical-VS-Other |
4.021400E-01 |
| Classical-VS-Normal |
6.75550004824998E-09 |
| Tall-VS-Follicular |
3.83620000000695E-05 |
| Tall-VS-Other |
1.082440E-01 |
| Tall-VS-Normal |
2.08829999999161E-05 |
| Follicular-VS-Other |
4.724600E-01 |
| Follicular-VS-Normal |
7.902800E-01 |
| Other-VS-Normal |
5.186000E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.597900E-03 |
| Normal-vs-N1 |
2.513800E-02 |
| N0-vs-N1 |
4.814000E-01 |
|
|
